RJFSA
RXDX

Raymond James Financial Services Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,036
Closed -$769K – 3415
2022
Q3 		$769K Buy
+13,036
New +$597K ﹤0.01% 1987

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Raymond James Financial Services Advisors's RXDX Position: Q4 2022 in Review

Raymond James Financial Services Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2022, closing a stake of 13,036 shares — an estimated $769K sold.

Raymond James Financial Services Advisors first reported a position in RXDX in Q3 2022 and held it in 1 quarter. The position peaked at $769K in Q3 2022. 221 funds tracked by Wall St. Rank hold RXDX as of Q4 2022.

  • Raymond James Financial Services Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 13,036 Prometheus Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $769K.
  • Raymond James Financial Services Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $769K in Q3 2022.
  • 221 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2022.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.